COLUMBUS, Ohio – The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) announces the following awards, honors, grants and more that were recently given to the organization, teams or individuals: Eight more Idea Grant projects funded at Ohio State by Pelotonia or Spielman Fund  Eight new research studies funded by Pelotonia or the Stefanie Spielman Fund for Breast Cancer Research will help teams of OSUCCC – James scientists pursue innovative research involving glioblastoma, triple-negative breast cancer, non-small cell lung cancer and acute myeloid leukemia, among other malignancies. The studies, which total over $1.19 million, will help these multidisciplinary teams produce early data that could lead to larger external funding from sources such as the National Cancer Institute. Idea Grants are typically funded for two-year periods. These latest awards are from the 2025 fall funding cycle. OSUCCC – James to host World Symposium for Lymphedema Surgery in April On April 10-12, the OSUCCC – James will host the 11th World Symposium for Lymphedema Surgery, a premier global meeting dedicated to advancing lymphatic research and lymphedema treatment strategies. This year’s interactive symposium will bring together leading researchers, surgeons and therapists from around the world to share the latest innovations, research findings and clinical breakthroughs in the field through workshops, poster and oral sessions, and hot-topic debates. The symposium will unfold at The Junto Hotel in Columbus, Ohio. Abstracts can be submitted until the deadline of Feb. 27. The Ohio State University designates this symposium for a maximum of 19.00 AMA PRA Category 1 Credits™. The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. Register here. Course directors are Min-Jeong Cho, MD, assistant clinical professor in the Department of Plastic and Reconstructive Surgery at Ohio State, and Roman Skoracki, MD, FRCSC, FACS, professor and director of the Division of Oncologic Plastic Surgery at Ohio State, and director the Stefanie Spielman Comprehensive Breast Center at the OSUCCC – James. International lung cancer congress yields MOU between NCI - Cairo University and OSUCCC – James A recent global congress on lung cancer culminated in a memorandum of understanding (MOU) between NCI - Cairo University and the OSUCCC – James that will help Ohio State expand its oncology footprint, foster collaborative research, and strengthen faculty and trainee exchanges between the institutions. The Egyptian government’s National Cancer Institute (NCI) is an educational, training and research institution affiliated with Cairo University.  Held Dec. 5-6 in Cairo, Egypt, the Oncothoracic International Association (ONTiC) congress was a premier convening of worldwide leaders in thoracic oncology that featured cutting-edge science and regionally tailored solutions under the theme “Global Excellence With Real Impact.”  Ohio State presenters at the congress were thoracic oncology specialists Christian Rolfo, MD, PhD, director of the Division of Medical Oncology; David Carbone, MD, PhD, co-leader of the Translational Therapeutics Program; Triparna Sen, PhD, associate director for research in the Division of Medical Oncology; Asrar Alahmadi, MBBS, assistant professor of Medical Oncology; and Roberto Borea, MD, postdoctoral researcher. Dr. Rolfo also is co-president of ONTiC. Carbone receives Lifetime Achievement Award for lung cancer research at international congress  David Carbone, MD, PhD, co-leader of the Translational Therapeutics Program and director of the Thoracic Oncology Center at the OSUCCC – James, received a Lifetime Achievement Award at the Oncothoracic International Association (ONTiC) congress held Dec. 5-6 in Cairo, Egypt, for his groundbreaking work as a thoracic clinician and researcher. Also at the congress, which was a convening of worldwide leaders in thoracic oncology that featured cutting-edge science under the theme “Global Excellence With Real Impact,” Dr. Carbone was recognized for his service as past president of the International Association for the Study of Lung Cancer (IASLC), a global organization dedicated to researching lung cancer and other thoracic malignancies.  In 2021, the IASLC presented Dr. Carbone with the Paul A. Bunn Jr. Scientific Award for his many career contributions to thoracic cancer research. At Ohio State, he is a professor in the Division of Medical Oncology and holds the Barbara J. Bonner Chair in Lung Cancer Research. His research is focused on proteomic and expression array signature development, genetics, immunotherapy and tumor-associated immunosuppression mechanisms in lung cancer. Ohio State recognized as Gold Standard Center of Excellence in Cardio-Oncology The International Cardio-Oncology Society (IC-OS) has recognized The Ohio State University as a Gold Standard Center of Excellence for “outstanding professional contributions to the field of cardio-oncology.” This is the highest standard available through the society, and the IC-OS is the only organization globally that offers such a designation. The distinction is effective through 2028. Adam Potter, MD, PhD, director of the Cardio-Oncology Program within the Division of Cardiovascular Medicine at Ohio State, received word about the recognition from officials at the IC-OS, a global group of medical professionals who collaborate to protect the cardiovascular health of all patients undergoing cancer therapy, striving to eliminate cardiovascular disease as a barrier to effective cancer treatment. New double transgenic model of MCL accelerates search for curative treatment A multi-center research team co-led by scientists at the OSUCCC – James has developed a mouse model of mantle cell lymphoma (MCL) that allows for testing of new therapies in the context of a functional immune system. Supported in part by funding from Pelotonia – the community and annual cycling event series that raises money for cancer research at Ohio State – the study was published in the journal Clinical Cancer Research. Lapo Alinari, MD, PhD, and Robert Baiocchi, MD, PhD, both of the Leukemia and Hematologic Malignancies (LHM) Program at the OSUCCC – James, were co-corresponding authors along with Samir Parekh, MD, PhD, of the Icahn School of Medicine at Mount Sinai, New York.   Zhu elected to HIV-associated cancers study section at NIH  Jian Zhu, PhD, a member of the Cancer Biology Program at the OSUCCC – James, has been elected to a four-year term as a standing member of the HIV Coinfections and HIV-Associated Cancers (HCAC) Study Section in the Infectious Diseases and Immunology B Integrated Review Group at the National Institutes of Health (NIH). Members are nominated for scientific achievements, including research accomplishments and publications. Dr. Zhu, a professor of Pathology and of Microbial Infection and Immunity, focuses his research on AIDS-associated malignancies, especially B-cell lymphomas and head and neck cancers. His group studies viral immunopathogenesis and oncogenesis of HIV and several oncoviruses (e.g., EBV, KSHV and HPV), with the aim of developing antiviral and antitumor therapies targeting these virus-associated tumors.  Media Contact: Mary Ellen Fiorino, Mary.Fiorino@osumc.edu